Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
According to the company, Epibase® analysis supports Pieris in the selection and optimization of Anticalins® with favorable properties including the lowest possible immunogenicity both in their internal projects and in collaborative projects with its partners.
"Pieris purposely selected human lipocalin scaffolds for therapeutic use because of their intrinsic properties. The chosen human lipocalins are small, non-glycosylated, highly stable monomeric binding proteins present in significant amounts in blood and other bodily fluids. Anticalins® are therefore expected to exhibit a low immunogenicity potential upon repeated parenteral use", says Dr. Andreas Hohlbaum, Pieris' Director of Science and Preclinical Development.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.